Loading clinical trials...
Loading clinical trials...
Phase I Study of Inotuzumab Ozogamicin With 3 and 4 Drug Augmented Berlin-Frankfurt-Münster (BFM) Re-Induction for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
Conditions
Interventions
Inotuzumab ozogamicin
Prednisone Pill
+5 more
Locations
4
United States
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
University of Virginia
Charlottesville, Virginia, United States
VCU Massey Cancer Center
Richmond, Virginia, United States
University of Wisconsin
Madison, Wisconsin, United States
Start Date
July 22, 2022
Primary Completion Date
July 15, 2023
Completion Date
July 1, 2026
Last Updated
August 22, 2023
NCT07523555
NCT06395103
NCT07223021
NCT05674175
NCT07429461
NCT06785818
Lead Sponsor
University of Virginia
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions